Publications

Detailed Information

Reproducibility of the kinetic analysis of 3 `-deoxy-3 `-[(18)F] fluorothymidine positron emission tomography in mouse tumor models

DC Field Value Language
dc.contributor.authorChoi, Seung Jin-
dc.contributor.authorKim, Seog Young-
dc.contributor.authorKim, Su Jin-
dc.contributor.authorLee, Jae Sung-
dc.contributor.authorPark, Soo Ah-
dc.contributor.authorYun, Sung-Cheol-
dc.contributor.authorOh, Seung Jun-
dc.contributor.authorKim, Jae Seung-
dc.contributor.authorMoon, Dae Hyuk-
dc.contributor.authorRyu, Jin Sook-
dc.contributor.authorKim, Sang-We-
dc.contributor.authorIm, Ki Chun-
dc.contributor.authorLee, Seung Jin-
dc.contributor.authorLee, Sang Ju-
dc.date.accessioned2012-07-03T07:16:28Z-
dc.date.available2012-07-03T07:16:28Z-
dc.date.issued2009-10-
dc.identifier.citationNUCLEAR MEDICINE AND BIOLOGY; Vol.36 7; 711-719ko_KR
dc.identifier.issn0969-8051-
dc.identifier.urihttps://hdl.handle.net/10371/78283-
dc.description.abstractObjectives: We assessed the reproducibility of the kinetic analysis of 3`-deoxy-3`-[(18)F]fluorothymidine (FLT) positron emission tomography (PET) in A431 human epidermoid carcinoma and murine Lewis lung carcinoma (LLC) tumor models. Methods: We injected 7.4 MBq of FLT (n=10 for each group) and acquired 2-h dynamic PET images. A second scan was performed I day later. We calculated standardized uptake value (SUV), kinetic rate constants, volume of distribution of phosphorylated FLT (V(dm)), net influx constant (K(FUT-CA)) and influx constant by Patlak graphical analysis (K(FLT-PA)). The percent difference between measurements of a parameter was calculated to compare the reproducibilities of different parameters. Results: FLT phosphorylation was higher in mice with A431 tumors than in mice with LLC tumors (P<005). Differences in the standard deviations of the percent differences of parameters were statistically significant (P<001) in each model. In mice with A431 tumors, SUV, V(dm), K(FLT-CA) and K(FLT-PA) had standard deviations of the percent difference of <= 20%. The most reproducible parameter was K(FLT-PA), although the standard deviation (15.6%) was not statistically different from those of V(dm) (15.8%), K(FLT-CA) (17.5%) and SUV (18.9%). In mice with LLC tumors, K(1), K(1)/k(2) and k(3) had standard deviations of the percent difference of <= 20%. No macroparameters reflecting a total FLT flux had standard deviations of <= 20%. Conclusion: Our results show the reproducibility of the kinetic macroparameters of FLT PET in mouse tumors with high FLT phosphorylation.ko_KR
dc.description.sponsorshipThis study was supported by the Real Time Molecular
Imaging Research Program of the Korean Science and
Engineering Foundation, which is funded by the Ministry
of Education, Science and Technology, Republic of Korea,
and by the Korea Health 21 R&D Project, Ministry of
Health, Welfare and Family Affairs, Republic of Korea
(grant no. A062254).
ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER SCIENCE INCko_KR
dc.subjectReproducibilityko_KR
dc.subjectKinetic analysisko_KR
dc.subjectMouseko_KR
dc.subjectPositron emission tomographyko_KR
dc.subject3 `-Deoxy-3 `-[(18)F]fluorothymidineko_KR
dc.titleReproducibility of the kinetic analysis of 3 `-deoxy-3 `-[(18)F] fluorothymidine positron emission tomography in mouse tumor modelsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor최승진-
dc.contributor.AlternativeAuthor김석영-
dc.contributor.AlternativeAuthor김수진-
dc.contributor.AlternativeAuthor이재성-
dc.contributor.AlternativeAuthor이상주-
dc.contributor.AlternativeAuthor박수아-
dc.contributor.AlternativeAuthor이승진-
dc.contributor.AlternativeAuthor윤성철-
dc.contributor.AlternativeAuthor임기춘-
dc.contributor.AlternativeAuthor오승준-
dc.contributor.AlternativeAuthor김상위-
dc.contributor.AlternativeAuthor김재승-
dc.contributor.AlternativeAuthor류진숙-
dc.contributor.AlternativeAuthor문대혁-
dc.identifier.doi10.1016/j.nucmedbio.2009.06.001-
dc.citation.journaltitleNUCLEAR MEDICINE AND BIOLOGY-
dc.description.citedreferenceKim SJ, 2008, J NUCL MED, V49, P2057, DOI 10.2967/jnumed.108.053215-
dc.description.citedreferenceBuck AK, 2007, EUR J NUCL MED MOL I, V34, P1775, DOI 10.1007/s00259-007-0452-z-
dc.description.citedreferenceKenny L, 2007, EUR J NUCL MED MOL I, V34, P1339, DOI 10.1007/s00259-007-0379-4-
dc.description.citedreferenceKim JS, 2007, J NUCL MED, V48, P1527, DOI 10.2967/jnumed.107.040550-
dc.description.citedreferenceLee SJ, 2007, EUR J NUCL MED MOL I, V34, P1406, DOI 10.1007/s00259-007-0391-8-
dc.description.citedreferenceSchiepers C, 2007, EUR J NUCL MED MOL I, V34, P1003, DOI 10.1007/s00259-006-0354-5-
dc.description.citedreferenceHerrmann K, 2007, CLIN CANCER RES, V13, P3552, DOI 10.1158/1078-0432.CCR-06-3025-
dc.description.citedreferenceWieder HA, 2007, EUR J NUCL MED MOL I, V34, P878, DOI 10.1007/s00259-006-0292-2-
dc.description.citedreferenceDandekar M, 2007, J NUCL MED, V48, P602, DOI 10.2967/jnumed.106.036608-
dc.description.citedreferenceTaschereau R, 2007, MED PHYS, V34, P1026, DOI 10.1118/1.2558115-
dc.description.citedreferenceMuzi M, 2006, J NUCL MED, V47, P1612-
dc.description.citedreferencePerumal M, 2006, CANCER RES, V66, P8558, DOI 10.1158/0008-5472.CAN-06-0898-
dc.description.citedreferenceReske SN, 2006, EUR J NUCL MED MOL I, V33, pS38, DOI 10.1007/s00259-006-0134-2-
dc.description.citedreferenceTwombly R, 2006, J NATL CANCER I, V98, P232, DOI 10.1093/jnci/djj086-
dc.description.citedreferencePio BS, 2006, MOL IMAGING BIOL, V8, P36, DOI 10.1007/s11307-005-0029-9-
dc.description.citedreferenceKelloff GJ, 2005, CLIN CANCER RES, V11, P7967, DOI 10.1158/1078-0432.CCR-05-1302-
dc.description.citedreferenceKenny LM, 2005, CANCER RES, V65, P10104-
dc.description.citedreferenceColozza M, 2005, ANN ONCOL, V16, P1723, DOI 10.1093/annonc/mdi352-
dc.description.citedreferenceShields AF, 2005, EUR J NUCL MED MOL I, V32, P1269, DOI 10.1007/s00259-005-1813-0-
dc.description.citedreferenceTseng JR, 2005, J NUCL MED, V46, P1851-
dc.description.citedreferenceGoffin J, 2005, CLIN CANCER RES, V11, P5928, DOI 10.1158/1078-0432.CCR-05-0130-
dc.description.citedreferenceLeyton J, 2005, CANCER RES, V65, P4202-
dc.description.citedreferenceMuzi M, 2005, J NUCL MED, V46, P274-
dc.description.citedreferenceMuzi M, 2005, J NUCL MED, V46, P371-
dc.description.citedreferenceWaldherr C, 2005, J NUCL MED, V46, P114-
dc.description.citedreferenceGrierson JR, 2004, NUCL MED BIOL, V31, P829, DOI 10.1016/j.nucmedbio.2004.06.004-
dc.description.citedreferenceOyama N, 2004, J NUCL MED, V45, P519-
dc.description.citedreferenceVisvikis D, 2004, EUR J NUCL MED MOL I, V31, P169, DOI 10.1007/s00259-003-1339-2-
dc.description.citedreferenceBarthel H, 2003, CANCER RES, V63, P3791-
dc.description.citedreferenceDittmann H, 2002, EUR J NUCL MED MOL I, V29, P1462, DOI 10.1007/s00259-002-0925-z-
dc.description.citedreferenceTherasse P, 2000, J NATL CANCER I, V92, P205-
dc.description.citedreferenceWeber WA, 1999, J NUCL MED, V40, P1771-
dc.description.citedreferenceShields AF, 1998, NAT MED, V4, P1334-
dc.description.citedreferenceMINN H, 1995, RADIOLOGY, V196, P167-
dc.description.citedreferenceCANELLOS GP, 1988, J CLIN ONCOL, V6, P931-
dc.description.tc3-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share